TVTX Travere Therapeutic
- 6.700
- +0.360+5.68%
Travere Therapeutic News
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Se
Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
In the last three months, 6 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rec
Travere Therapeutics Shares Are Trading Higher Following Q1 Earnings.
Travere Therapeutics Shares Are Trading Higher Following Q1 Earnings.
Canadian Investment Banking Group: Maintaining the Travere Therapeutics (TVTX.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $15.00 to $18.00.
Canadian Investment Banking Group: Maintaining the Travere Therapeutics (TVTX.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $15.00 to $18.00.
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $18
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics with a Buy and raises the price target from $15 to $18.
Earnings Call Summary | Travere Therapeutic(TVTX.US) Q1 2024 Earnings Conference
The following is a summary of the Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript:Financial Performance:Travere recorded Q1 2024 total revenue of $41.4 million, up from $30.9 millio
Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
Travere Therapeutic | 10-Q: Quarterly report
Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate of $(0.99) by 52.53 percent. This is a 64.13 percent decrease over losses
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, Vs. Street Est of $43.6M
04:07 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M
Travere Therapeutics 1Q Rev $41.4M >TVTX
Travere Therapeutics 1Q Rev $41.4M >TVTX
Travere Therapeutics 1Q Loss/Shr $1.76 >TVTX
Travere Therapeutics 1Q Loss/Shr $1.76 >TVTX
Press Release: Travere Therapeutics Reports First Quarter 2024 Financial Results
Travere Therapeutics Reports First Quarter 2024 Financial Results FDA grants Priority Review for sNDA to convert FILSPARI(R) (sparsentan) from accelerated approval to full approval for the treatment
Travere Therapeutics Reports First Quarter 2024 Financial Results
Press Release: Travere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics to Report First Quarter 2024 Financial Results SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report firs
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Price Target Raised to $19.00/Share From $17.00 by HC Wainwright & Co.
Travere Therapeutics Price Target Raised to $19.00/Share From $17.00 by HC Wainwright & Co.
HC Wainwright & Co. : Travere Therapeutics (TVTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $19.00.
HC Wainwright & Co. : Travere Therapeutics (TVTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $19.00.
Analysis
Price Target
No Data
